Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Therapy with the oral antidiabetic agent troglitazone (Rezulin) has been associated with cases of severe hepatotoxicity and drug-induced liver failure, which led to the recent withdrawal of the product from the U.S. market. While the mechanism of this toxicity remains unknown, it is possible that chemically reactive metabolites of the drug play a causative role. In an effort to address this possibility, this study was undertaken to determine whether troglitazone undergoes metabolism in human liver microsomal preparations to electrophilic intermediates. Following incubation of troglitazone with human liver microsomes and with cDNA-expressed cytochrome P450 isoforms in the presence of glutathione (GSH), a total of five GSH conjugates (M1-M5) were detected and identified tentatively by LC-MS/MS analysis. In two cases (M1 and M5), the structures of the adducts were confirmed by NMR spectroscopy and/or by comparison with an authentic standard prepared by synthesis. The formation of GSH conjugates M1-M5 revealed the operation of two distinct metabolic activation pathways for troglitazone, one of which involves oxidation of the substituted chromane ring system to a reactive o-quinone methide derivative, while the second involves a novel oxidative cleavage of the thiazolidinedione (TZD) ring, potentially generating highly electrophilic alpha-ketoisocyanate and sulfenic acid intermediates. When troglitazone was administered orally to a rat, samples of bile were found to contain GSH conjugates which reflected the operation of these same metabolic pathways in vivo. The finding that metabolism of the TZD ring of troglitazone was catalyzed selectively by P450 3A enzymes is significant in light of the recent report that troglitazone is an inducer of this isoform in human hepatocytes. The implications of these results are discussed in the context of the potential for troglitazone to covalently modify hepatic proteins and to cause oxidative stress through redox cycling processes, either of which may play a role in drug-induced liver injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mechanistic studies subsequently identified bioactivation by CYP3A4 and CYP2C8 to reactive quinone-like metabolites and ring-opened sulfenic acid intermediates that covalently bind cellular macromolecules and trigger mitochondrial injury, neither of which was reliably flagged by standard preclinical hepatotoxicity assays [75,76].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“Fialuridine (Section 7.1) and troglitazone (Section 7.4) are intrinsic toxicodynamic failures, driven by human-relevant mitochondrial injury and reactive-metabolite formation, respectively.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“Troglitazone, the first marketed thiazolidinedione, was withdrawn after reports of severe idiosyncratic hepatotoxicity, including fulminant liver failure and transplantation.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76]”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“Fourth, idiosyncratic toxicities, such as those underlying the fialuridine and troglitazone failures, are by definition not captured by any pharmacokinetic scaling framework, and even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
Citations
Cites
Hepatic Dysfunction Associated with Troglitazone
Watkins, P. B., & Whitcomb, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381314 · Cited by 446
Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone
Gitlin, N., Julie, N. L., Spurr, C. L., Lim, K. N., & Juarbe, H. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00008 · Cited by 230
Yoshioka, T., Fujita, T., Kanai, T., Aizawa, Y., Kurumada, T., Hasegawa, K., & Horikoshi, H. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00122a022 · Cited by 221
Kohlroser, J., Mathai, J., Reichheld, J., Banner, B. F., & Bonkovsky, H. L. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01707.x · Cited by 209
Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00009 · Cited by 195
Kassahun, K., Hu, P. L., Grillo, M. P., Davis, M. R., Jin, L., & Baillie, T. A. (1994) · Chemico-Biological Interactions · doi:10.1016/0009-2797(94)90014-0 · Cited by 74
Self-citationOhe, T., Mashino, T., & Hirobe, M. (1994) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1994.1185 · Cited by 64
Davis, M. R., Kassahun, K., Jochheim, C. M., Brandt, K. M., & Baillie, T. A. (1993) · Chemical Research in Toxicology · doi:10.1021/tx00033a020 · Cited by 44
Self-citation
Research works printed but not linked: 16
- Henry R. R., 1997, Thiazolidinones. Curr. Ther. Diabetes 26, 553−573
- Hu J., 1999, J. Org. Chem., 64
- Hart T. W., 1985, Tetrahedron Lett., 26
- Baillie T. A., 1993, Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22, 319−325
- Kassahun K., 1997, Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: Identification of Phase I metabolites and glutathione conjugates. Chem. Res. Toxicol. 10, 1228−1233
- Borel A. G., 1993, Identification of carbomoylated thiol conjugates as metabolites of the antineoplastic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, in rats and humans. Drug Metab. Dispos. 21, 889−901
- Kawai K., 1997, Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneim.-Forsch. 47, 356−368
- Loi C. M., 1997, J. Clin. Pharmacol., 37
- Ohe T., 1997, Substituent elimination from p-substituted phenols by cytochrome P450. ipso-Substitution by the oxygen atom of the active species. Drug Metab. Dispos. 25, 116−122
- Ohe T., 2000, Novel metabolic pathway of estrone and 17β-estradiol catalyzed by cytochrome P-450. Drug Metab. Dispos. 28, 110−112
- Yamazaki H., 1999, Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab. Dispos. 27, 1260−1266
- He K., 1999, Proceedings of the 9th North American ISSX Meeting, #207
- Polsker G. L., 1999, Troglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs 57, 409−438
- Ramachandran V., 1999, Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab. Dispos. 27, 1194−1199
- Mansuy D., 1991, J. Am. Chem. Soc., 113
- Abbreviations TZD, thiazolidinedione
Cited by
Cytochrome P450 and Chemical Toxicology
Guengerich, F. P. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700079z · Cited by 1,725
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Self-citationStepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Self-citationo-Quinone methides: intermediates underdeveloped and underutilized in organic synthesis
Water, R. W. V. D., & Pettus, T. R. R. (2002) · Tetrahedron · doi:10.1016/s0040-4020(02)00496-9 · Cited by 587
Metadata
- Authors
- Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., & Baillie, T. A.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kassahun, Kelem
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-12-08
- Volume
- 14
- Issue
- 1
- Pages
- 62-70
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- OpenAlex
- W2068532562
- Cited by
- 311
- References
- 8
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 6 · 2023: 7 · 2022: 9 · 2021: 10 · 2020: 5 · 2019: 4 · 2018: 10 · 2017: 8 · 2016: 8 · 2015: 9 · 2014: 15 · 2013: 12 · 2012: 16
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Research in Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- troglitazone, drug metabolism, reactive metabolites, glutathione conjugates, CYP3A, hepatotoxicity, drug-induced liver injury, sulfenic acid, oxidative stress, redox cycling, covalent protein modification, human liver microsomes, bile
- MeSH terms
- Troglitazone, Animals, Bile, Biotransformation, Catalysis, Chromans, Chromatography, Liquid, Cytochrome P-450 Enzyme System, Glutathione, Humans, Hypoglycemic Agents, Isoenzymes, Ketoconazole, Kinetics, Microsomes, Liver, NADP, Mass Spectrometry, Steroid Hydroxylases, Thiazoles, Thiazolidinediones, Rats, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission. https://app.cochat.ai/papers/10.1021/tx000180q
- The paper
- Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., & Baillie, T. A. (2001). Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission. Chemical Research in Toxicology. https://doi.org/10.1021/tx000180q
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.